Want to see XFOR full AI Analyst Report?
Earnings Data
Report Date
Oct 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
―Last Year’s EPS
-0.69Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.Company Guidance
Clinical Trial Advancements
X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.
US Patent Allowance
Received a notice of allowance from the US patent office for using mavorixafor to treat severe chronic idiopathic and autoimmune neutropenia, with an expiration date in March 2041.
Global Expansion Efforts
Mavorixafor's MAA was accepted by European authorities, with potential EMA approval expected by Q1 2026. New partnerships established for commercialization in Europe, Australia, New Zealand, and the MENA region.
Financial Position
Ended Q1 2025 with nearly $90 million in cash and equivalents, with sufficient funds to support operations into the first half of 2026.
Positive Market Research for CN
Completed a survey with 95 US physicians, revealing higher case loads and a clear unmet need in the CN market.
XFOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XFOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $4.20 | $4.38 | +4.29% |
Mar 17, 2026 | $3.56 | $4.23 | +18.82% |
Nov 05, 2025 | $3.97 | $3.55 | -10.58% |
Jul 31, 2025 | $1.77 | $1.68 | -5.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does X4 Pharmaceuticals (XFOR) report earnings?
X4 Pharmaceuticals (XFOR) is schdueled to report earning on Oct 29, 2026, Before Open (Confirmed).
What is X4 Pharmaceuticals (XFOR) earnings time?
X4 Pharmaceuticals (XFOR) earnings time is at Oct 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XFOR EPS forecast?
Currently, no data Available